Firma ViGeneron, Autor bei Presse-Blog

Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron´s REVeRT technology

25. Oktober 202326. Oktober 2023 Firma ViGeneronForschung und Entwicklungaav, abca4, brain, crispr, packaging, patients, pigmentosa, retinal, retinitis, stargardt, trans, vg801, vg901, vigeneron, with

REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packaging size in various tissues Potential to address prevalent inherited diseases caused by larger genes such as Stargardt disease Delivery of CRISPR Mehr

ViGeneron announces EMA Approval of Clinical Trial Application for VG901, a gene therapy to treat Retinitis Pigmentosa

22. August 202322. August 2023 Firma ViGeneronForschung und Entwicklungaav, atu, can, clinical, cng, eyesight, its, ocular, patients, pigmentosa, retinal, retinitis, vg901, vgaav, vigeneron

ViGeneron GmbH (ViGeneron), a next-generation gene therapy company, today announced that the European Medicines Agency (EMA) has approved the Clinical Trial Application (CTA) for VG901, a potentially transformative gene therapy to treat CNGA1-associated Retinitis Pigmentosa (RP), an ocular disorder currently Mehr

ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT

11. Oktober 202211. Oktober 2022 Firma ViGeneronForschung und Entwicklungaav, cell, cells, packaging, patients, pigmentosa, retinal, retinitis, stargardt, trans, vg901, vgaav, vigeneron, vigenerons, with

Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development ViGeneron GmbH, a next-generation gene therapy company, today announced Mehr

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

26. April 202226. April 2022 Firma ViGeneronKooperationen / Fusionencells, daiichi, financial, injection, new, patients, research, retinal, sankyo, therapy, treatment, vgaav, vigeneron, vigenerons, with

ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye Mehr

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

6. April 2022 Firma ViGeneronForschung und Entwicklung??royalties??, aav, cells, clinical, cns, injection, ophthalmic, patients, payment, retinal, therapy, vgaav, vigeneron, vigenerons, with

Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, Mehr

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

18. Januar 202112. April 2021 Firma ViGeneronForschung und Entwicklungcells, collateral, daiichi, financial, injection, medical, ophthalmic, patients, research, sankyo, therapy, treatment, vigeneron, vigenerons, with

ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a Mehr

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

5. Januar 202112. April 2021 Firma ViGeneronMedizintechnik??royalties??, aav, cells, clinical, medical, patients, payment, poc, research, retinal, therapy, vgaav, vigeneron, vigenerons, with

. – Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target – The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections Mehr

ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

1. Dezember 202012. April 2021 Firma ViGeneronKooperationen / Fusionenaav, apptec, atu, cell, cells, market, ophthalmic, patients, pigmentosa, retinal, retinitis, vgaav, vigeneron, vigenerons, with

ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), today announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy Mehr

Autor: Firma ViGeneron